Compass Therapeutics, Inc.
CMPXNASDAQHealthcare● Active
$2.05
+$0.01(+0.31%)
Market Cap$282975258
P/E Ratio—
52W High$6.88
52W Low$1.61
Compass Therapeutics, Inc. (CMPX) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
CMPX · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: May 5, 2026EPS Actual
-$0.10
Est. -$0.10 · +0.0%
Revenue
—
Est. $-0.00B
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 5, 2026
After Market Close
✓ 3-Quarter EPS Beat Streak
CMPX reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 10, 2026 | -$0.10 | — | — | — | $-0.00B | — |
| — Q2 FY2026 | May 5, 2026 | -$0.10 | -$0.10 | +0.0% | — | $-0.00B | — |
| ▲ Q1 FY2026 | Mar 5, 2026 | -$0.10 | -$0.09 | +10.0% | — | $-0.00B | — |
| ▲ Q4 FY2025 | Nov 5, 2025 | -$0.14 | -$0.08 | +42.9% | — | — | — |
| ▼ Q3 FY2025 | Aug 11, 2025 | -$0.13 | -$0.14 | -7.7% | — | — | — |
| — Q2 FY2025 | May 8, 2025 | -$0.12 | -$0.12 | +0.0% | — | — | — |
| ▼ Q1 FY2025 | Feb 27, 2025 | -$0.10 | -$0.11 | -10.0% | — | — | — |
| ▲ Q4 FY2024 | Nov 12, 2024 | -$0.11 | -$0.08 | +27.3% | — | — | — |
Q3 FY2026
Aug 10, 2026
EPS Actual
—
EPS Est.
-$0.10
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 5, 2026
EPS Actual
-$0.10
EPS Est.
-$0.10
EPS Surpr.
+0.0%
Revenue
—
Q1 FY2026
Mar 5, 2026Beat
EPS Actual
-$0.09
EPS Est.
-$0.10
EPS Surpr.
+10.0%
Revenue
—
Q4 FY2025
Nov 5, 2025Beat
EPS Actual
-$0.08
EPS Est.
-$0.14
EPS Surpr.
+42.9%
Revenue
—
Q3 FY2025
Aug 11, 2025Miss
EPS Actual
-$0.14
EPS Est.
-$0.13
EPS Surpr.
-7.7%
Revenue
—
Q2 FY2025
May 8, 2025
EPS Actual
-$0.12
EPS Est.
-$0.12
EPS Surpr.
+0.0%
Revenue
—
Q1 FY2025
Feb 27, 2025Miss
EPS Actual
-$0.11
EPS Est.
-$0.10
EPS Surpr.
-10.0%
Revenue
—
Q4 FY2024
Nov 12, 2024Beat
EPS Actual
-$0.08
EPS Est.
-$0.11
EPS Surpr.
+27.3%
Revenue
—
Analyst Estimates
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $0.02 | $0.02 | $0.02 | 4 |
| Q3 FY2028 | $-0.00 | $-0.00 | $-0.00 | 6 |
| Q2 FY2028 | $-0.02 | $-0.02 | $-0.02 | 4 |
| Q1 FY2028 | $-0.05 | $-0.05 | $-0.05 | 4 |
| Q4 FY2027 | $-0.07 | $-0.07 | $-0.07 | 3 |
| Q3 FY2027 | $-0.10 | $-0.10 | $-0.10 | 4 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $0.0B | $0.0B | $0.0B | 8 |
| Q3 FY2028 | $0.0B | $0.0B | $0.0B | 6 |
| Q2 FY2028 | $0.0B | $0.0B | $0.0B | 5 |
| Q1 FY2028 | $0.0B | $0.0B | $0.0B | 5 |
| Q4 FY2027 | $0.0B | $0.0B | $0.0B | 6 |
| Q3 FY2027 | $0.0B | $0.0B | $0.0B | 6 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | May 5, 2026 | +0.0% | $1.94 | $1.95 | +0.52% |
| ▲ Q1 FY2026 | Mar 5, 2026 | +10.0% | $5.69 | $5.53 | -2.81% |
| ▲ Q4 FY2025 | Nov 5, 2025 | +42.9% | $3.79 | $3.82 | +0.79% |
| ▼ Q3 FY2025 | Aug 11, 2025 | -7.7% | $2.70 | $3.34 | +23.70% |
| ▲ Q2 FY2025 | May 8, 2025 | +0.0% | $1.76 | $1.78 | +1.14% |
| ▼ Q1 FY2025 | Feb 27, 2025 | -10.0% | $2.97 | $2.92 | -1.68% |
| ▲ Q4 FY2024 | Nov 12, 2024 | +27.3% | $1.90 | $1.79 | -5.79% |
| ▲ Q3 FY2024 | Aug 12, 2024 | +0.0% | $1.09 | $1.13 | +3.67% |
Q2 FY2026+0.52%
Report Date
May 5, 2026
EPS Beat/Miss
+0.0%
Price Before
$1.94
Price After
$1.95
Q1 FY2026-2.81%
Report Date
Mar 5, 2026
EPS Beat/Miss
+10.0%
Price Before
$5.69
Price After
$5.53
Q4 FY2025+0.79%
Report Date
Nov 5, 2025
EPS Beat/Miss
+42.9%
Price Before
$3.79
Price After
$3.82
Q3 FY2025+23.70%
Report Date
Aug 11, 2025
EPS Beat/Miss
-7.7%
Price Before
$2.70
Price After
$3.34
Q2 FY2025+1.14%
Report Date
May 8, 2025
EPS Beat/Miss
+0.0%
Price Before
$1.76
Price After
$1.78
Q1 FY2025-1.68%
Report Date
Feb 27, 2025
EPS Beat/Miss
-10.0%
Price Before
$2.97
Price After
$2.92
Q4 FY2024-5.79%
Report Date
Nov 12, 2024
EPS Beat/Miss
+27.3%
Price Before
$1.90
Price After
$1.79
Q3 FY2024+3.67%
Report Date
Aug 12, 2024
EPS Beat/Miss
+0.0%
Price Before
$1.09
Price After
$1.13
Avg Beat Reaction-0.41%
Avg Miss Reaction+11.01%
Beat Rate6 / 8 quarters
Largest Move+23.70% (Q3 FY2025)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: CMPX ends December
Compass Therapeutics, Inc. (CMPX) most recently reported earnings on May 5, 2026 for Q2 FY2026, posting EPS of $-0.10 (in line with the analyst consensus of $-0.10). CMPX has beaten EPS estimates for 3 consecutive quarters. The next CMPX earnings date is expected around September 1, 2026.
Each quarter, investors track CMPX earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. CMPX revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
CMPX's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
CMPX earnings · 4 questionsCompass Therapeutics, Inc.'s next earnings report is expected around September 1, 2026. CMPX typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; CMPX historically reports after market close (AMC).
CMPX earnings datewhen is CMPX earningsCMPX next earnings datewhen does CMPX report earningsCMPX earnings calendar
▸ Source: FMP · Compass Therapeutics, Inc. SEC filings · US GAAP · Compass Therapeutics, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026